- Home
- PMI vs IMAB Comparison
PMI vs IMAB Comparison
Compare PMI & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMI
- IMAB
- Stock Information
- Founded
- PMI 1981
- IMAB 2014
- Country
- PMI United States
- IMAB United States
- Employees
- PMI N/A
- IMAB N/A
- Industry
- PMI
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- PMI
- IMAB Health Care
- Exchange
- PMI Nasdaq
- IMAB Nasdaq
- Market Cap
- PMI 605.1M
- IMAB 486.4M
- IPO Year
- PMI 2025
- IMAB 2020
- Fundamental
- Price
- PMI $4.05
- IMAB $4.64
- Analyst Decision
- PMI
- IMAB Strong Buy
- Analyst Count
- PMI 0
- IMAB 6
- Target Price
- PMI N/A
- IMAB $7.50
- AVG Volume (30 Days)
- PMI 3.4M
- IMAB 2.2M
- Earning Date
- PMI 12-16-2025
- IMAB 11-14-2025
- Dividend Yield
- PMI N/A
- IMAB N/A
- EPS Growth
- PMI N/A
- IMAB N/A
- EPS
- PMI N/A
- IMAB N/A
- Revenue
- PMI $4,461,000.00
- IMAB N/A
- Revenue This Year
- PMI N/A
- IMAB N/A
- Revenue Next Year
- PMI N/A
- IMAB N/A
- P/E Ratio
- PMI N/A
- IMAB N/A
- Revenue Growth
- PMI 1.36
- IMAB N/A
- 52 Week Low
- PMI $3.25
- IMAB $0.60
- 52 Week High
- PMI $13.68
- IMAB $6.79
- Technical
- Relative Strength Index (RSI)
- PMI N/A
- IMAB 48.87
- Support Level
- PMI N/A
- IMAB $4.13
- Resistance Level
- PMI N/A
- IMAB $6.79
- Average True Range (ATR)
- PMI 0.00
- IMAB 0.67
- MACD
- PMI 0.00
- IMAB -0.14
- Stochastic Oscillator
- PMI 0.00
- IMAB 19.17
About PMI Picard Medical Inc.
Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing an implantable Total Artificial Heart. It is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including TAH. The TAH is an implantable system designed to assume the full function of a failed human heart in patients suffering from advanced heart failure.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).